Latvia vs Serbia: Death rate from cancer
Latvia
319.58 deaths per 100,000 people
in 2021
Serbia
312.25 deaths per 100,000 people
in 2021
Latvia rank
4th
Serbia rank
5th
Death rate from cancer over time
- Latvia
- Serbia
How they compare
Latvia currently reports 319.58 deaths per 100,000 people against 312.25 deaths per 100,000 people in Serbia, a difference of 7.33 deaths per 100,000 people.
The two have swapped places 11 times across 22 shared years of data; in 2000 it was Serbia ahead.
Latvia ranks 4th and Serbia ranks 5th of 194 countries.
Across the 3 decades both report, Latvia averaged higher in 1 and Serbia in 2.
Head to head by decade
| Decade | Latvia | Serbia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 274.97 deaths per 100,000 people | 278.04 deaths per 100,000 people | 3.08 deaths per 100,000 people | Serbia |
| 2010s | 311.91 deaths per 100,000 people | 312.44 deaths per 100,000 people | 0.525 deaths per 100,000 people | Serbia |
| 2020s | 325.03 deaths per 100,000 people | 317.29 deaths per 100,000 people | 7.74 deaths per 100,000 people | Latvia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher death rate from cancer, Latvia or Serbia?
- Latvia, at 319.58 deaths per 100,000 people against 312.25 deaths per 100,000 people in Serbia as of 2021.
- What is the difference in death rate from cancer between Latvia and Serbia?
- 7.33 deaths per 100,000 people, with Latvia ahead.
- How many years of comparable data are there for Latvia and Serbia?
- 22 years are reported by both, from 2000 to 2021.
- How do Latvia and Serbia rank globally for death rate from cancer?
- Latvia ranks 4th and Serbia ranks 5th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) – with major processing by Our World in Data, published as Death rate from cancer. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of deaths from malignant neoplasms in both sexes, per 100,000 people.